Metabolism of [123I]epidepride may affect brain dopamine D2 receptor imaging with single-photon emission tomography

被引：7

作者：

Bergström, KA ^{[1
]}

Yu, MX

Kuikka, JT

Åkerman, KK

Hiltunen, J

Lehtonen, J

Halldin, C

Tiihonen, J

机构：

[1] Kuopio Univ Hosp, Dept Clin Physiol & Nucl Med, FIN-70210 Kuopio, Finland

[2] MAP Med Technol Oy, FIN-41160 Tikkakoski, Finland

[3] Univ Kuopio, Dept Psychiat, FIN-70210 Kuopio, Finland

[4] Karolinska Hosp, Karolinska Inst, Dept Clin Neurosci, Psychiat Sect, S-17176 Stockholm, Sweden

[5] Univ Kuopio, Niuvanniemi Hosp, Dept Forens Psychiat, FIN-70240 Kuopio, Finland

来源：

EUROPEAN JOURNAL OF NUCLEAR MEDICINE | 2000年 / 27卷 / 02期

关键词：

epidepride; metabolites; single-photon emission tomography; high-performance liquid chromatography;

D O I：

10.1007/s002590050028

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Iodine-123 labelled epidepride is a novel radiopharmaceutical for the study of cerebral dopamine D-2 receptors using single-photon emission tomography (SPET). A lipophilic labelled metabolite of [I-123]epidepride which may enter the brain and hamper the quantitation of receptors has been observed in human plasma. In the present study, gradient high-performance Liquid chromatography (HPLC) was used to investigate the plasma concentration of the lipophilic labelled metabolite and its correlation to SPET imaging of striatal dopamine D-2 receptors, A linear regression fit showed a negative correlation between the amount of the lipophilic labelled metabolite and the striatum to cerebellum ratio (n=16, R=-0.58, P<0.02), suggesting that plasma metabolite analysis is essential when imaging dopamine D-2 receptors with SPET using [I-123]epidepride.

引用

页码：206 / 208

页数：3

共 12 条

[1]

Bergstrom K. A., 1997, Journal of Labelled Compounds and Radiopharmaceuticals, V40, P151

[2]

Bergstrom KA, 1996, HUM PSYCHOPHARM CLIN, V11, P483, DOI 10.1002/(SICI)1099-1077(199611)11:6<483::AID-HUP818>3.3.CO

[3]

2-0

[4]

Halldin C., 1995, Journal of Labelled Compounds and Radiopharmaceuticals, V37, P709

[5]

HALLDIN C, 1995, J NUCL MED, V36, P1275

[6] VISUALIZATION OF EXTRASTRIATAL DOPAMINE D(2)-RECEPTORS IN THE HUMAN BRAIN [J].

KESSLER, RM ;

MASON, NS ;

VOTAW, JR ;

DEPAULIS, T ;

CLANTON, JA ;

ANSARI, MS ;

SCHMIDT, DE ;

MANNING, RG ;

BELL, RL .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 223 (01) :105-107

[7] SPECT IMAGING OF DOPAMINE-RECEPTORS WITH [I-123] EPIDEPRIDE - CHARACTERIZATION OF UPTAKE IN THE HUMAN BRAIN [J].

KORNHUBER, J ;

BRUCKE, T ;

ANGELBERGER, P ;

ASENBAUM, S ;

PODREKA, I .

JOURNAL OF NEURAL TRANSMISSION-GENERAL SECTION, 1995, 101 (1-3) :95-103

[8]

Kuikka JT, 1997, EUR J NUCL MED, V24, P483

[9] Limbic selectivity of clozapine [J].

Pilowsky, LS ;

Mulligan, RS ;

Acton, PD ;

Ell, PJ ;

Costa, DC ;

Kerwin, RW .

LANCET, 1997, 350 (9076) :490-491

[10] Dopamine transporter and D2-receptor density in late-onset alcoholism [J].

Repo, E ;

Kuikka, JT ;

Bergström, KA ;

Karhu, J ;

Hiltunen, J ;

Tiihonen, J .

PSYCHOPHARMACOLOGY, 1999, 147 (03) :314-318

← 1 2 →